This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krug, L. M. Articles by Livingston, P. O. Search for Related Content PubMed PubMed Citation Articles by Krug, L. M. Articles by Livingston, P. O.

Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin

¹ Thoracic Oncology Service and ² Laboratory of Tumor Vaccinology, Department of Medicine, and ³ Laboratory of Bioorganic Chemistry, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York

Purpose: Immunotherapy directed toward cell surface antigens may provide a novel approach to the eradication of chemoresistant micrometastatic disease in patients with small-cell lung cancer (SCLC). Studies in SCLC cell lines and human tissues suggest that the ganglioside fucosyl GM1 is an abundant yet specific target. A prior clinical study demonstrated the potent immunogenicity of fucosyl GM-1 derived from bovine thyroid gland, conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 adjuvant.

Experimental Design: We tested the immunogenicity of three different doses of a synthetic version of fucosyl-GM1 in patients with SCLC after a major response to initial therapy. The primary end point was to establish the lowest effective dose capable of inducing antibody production.

Results: Five of six patients at the 30-µg dose and three of five patients at the 10-µg dose mounted IgM responses of 1:80 or greater. These antibodies were confirmed by flow cytometry in seven of eight cases. None of the patients at the 3-µg dose had titers above 1:80. One patient at the 30-µg dose had an IgG response with a titer of 1:80. The sera from six of the eight responders induced potent complement-mediated cytotoxicity of tumor cells.

Conclusions: Vaccination with the synthetic fucosyl GM1-KLH conjugate induces an IgM antibody response against fucosyl GM1 and tumor cells expressing fucosyl GM1, comparable with the response induced by the bovine derivative. We plan to combine synthetic fucosyl GM1 vaccine at a dose of 30 µg with vaccines against three other antigens—GM2, Globo H, and polysialic acid—to test in patients with SCLC after initial chemotherapy.

This article has been cited by other articles:

				M.-O. Sadoulet, C. Franceschi, M. Aubert, F. Silvy, J.-P. Bernard, D. Lombardo, and E. Mas Glycoengineering of {alpha}Gal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope Glycobiology, June 1, 2007; 17(6): 620 - 630. [Abstract] [Full Text] [PDF]

				B. Ma, J. L. Simala-Grant, and D. E. Taylor Fucosylation in prokaryotes and eukaryotes Glycobiology, December 1, 2006; 16(12): 158R - 184R. [Abstract] [Full Text] [PDF]

				K. E. Krueger and S. Srivastava Posttranslational Protein Modifications: Current Implications for Cancer Detection, Prevention, and Therapeutics Mol. Cell. Proteomics, October 1, 2006; 5(10): 1799 - 1810. [Full Text] [PDF]

				N. Tokuda, Q. Zhang, S. Yoshida, S. Kusunoki, T. Urano, K. Furukawa, and K. Furukawa Genetic mechanisms for the synthesis of fucosyl GM1 in small cell lung cancer cell lines Glycobiology, October 1, 2006; 16(10): 916 - 925. [Abstract] [Full Text] [PDF]

				H. Geyer, M. Wuhrer, A. Resemann, and R. Geyer Identification and Characterization of Keyhole Limpet Hemocyanin N-Glycans Mediating Cross-reactivity with Schistosoma mansoni J. Biol. Chem., December 9, 2005; 280(49): 40731 - 40748. [Abstract] [Full Text] [PDF]

				L. E. Raez, S. Fein, and E. R. Podack Lung Cancer Immunotherapy Clin. Med. Res., November 1, 2005; 3(4): 221 - 228. [Abstract] [Full Text] [PDF]

				G. Giaccone, C. Debruyne, E. Felip, P. B. Chapman, S. C. Grant, M. Millward, L. Thiberville, G. D'addario, C. Coens, L. S. Rome, et al. Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) J. Clin. Oncol., October 1, 2005; 23(28): 6854 - 6864. [Abstract] [Full Text] [PDF]